383 related articles for article (PubMed ID: 25796589)
41. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
42. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
43. C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome.
Bobart SA; Sethi S; Fervenza FC
Kidney Med; 2019; 1(1):36-39. PubMed ID: 32734182
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological features of C3 glomerulopathy in children: a single-center experience.
Drake KA; Ellington N; Gattineni J; Torrealba JR; Hendricks AR
Pediatr Nephrol; 2020 Jan; 35(1):153-162. PubMed ID: 31667615
[TBL] [Abstract][Full Text] [Related]
45. A Case of Switch from C3 Glomerulonephritis to Proliferative Glomerulonephritis with Monoclonal IgG Deposits.
Zhang F; Gao E; Liang S; Yang N; Wang J
Ann Clin Lab Sci; 2018 Jul; 48(4):528-533. PubMed ID: 30143498
[TBL] [Abstract][Full Text] [Related]
46. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
47. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
[TBL] [Abstract][Full Text] [Related]
48. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.
Avasare RS; Canetta PA; Bomback AS; Marasa M; Caliskan Y; Ozluk Y; Li Y; Gharavi AG; Appel GB
Clin J Am Soc Nephrol; 2018 Mar; 13(3):406-413. PubMed ID: 29326307
[TBL] [Abstract][Full Text] [Related]
49. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
50. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
51. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.
Caravaca-Fontán F; Díaz-Encarnación MM; Lucientes L; Cavero T; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez A; Pérez de José A; Rabasco C; Rodado R; Fernández L; Pérez Gómez V; Ávila AI; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Rodríguez E; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; Cano-Megías M; González F; Shabaka A; López-Rubio ME; Fenollosa MÁ; Martín-Penagos L; Da Silva I; Alonso Titos J; Rodríguez de Córdoba S; Goicoechea de Jorge E; Praga M;
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1287-1298. PubMed ID: 32816888
[TBL] [Abstract][Full Text] [Related]
52. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
[TBL] [Abstract][Full Text] [Related]
53. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP; Esposito P; Rossini M
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947692
[TBL] [Abstract][Full Text] [Related]
54. Treatment of C3 glomerulopathy with complement blockers.
Vivarelli M; Emma F
Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
[TBL] [Abstract][Full Text] [Related]
55. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy.
Giaime P; Daniel L; Burtey S
Clin Nephrol; 2015 Jan; 83(1):57-60. PubMed ID: 24472365
[TBL] [Abstract][Full Text] [Related]
56. Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation.
Naseer MS; Singh A; Singh N
Glomerular Dis; 2022 Apr; 2(2):100-105. PubMed ID: 36751532
[TBL] [Abstract][Full Text] [Related]
57. [C3 glomerulopathy].
Chauvet S; Servais A; Frémeaux-Bacchi V
Nephrol Ther; 2014 Apr; 10(2):78-85. PubMed ID: 24508002
[TBL] [Abstract][Full Text] [Related]
58. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.
Ravindran A; Fervenza FC; Smith RJH; De Vriese AS; Sethi S
Mayo Clin Proc; 2018 Aug; 93(8):991-1008. PubMed ID: 30077216
[TBL] [Abstract][Full Text] [Related]
59. C3 glomerulonephritis associated with ANCA positivity: a case report.
Li L; Liu LQ; Yang YY; Hu ZX
BMC Nephrol; 2021 Apr; 22(1):143. PubMed ID: 33882866
[TBL] [Abstract][Full Text] [Related]
60. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
